We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Precancerous Breast Changes in Women with BRCA Gene Identified Using MR Spectroscopy

By MedImaging International staff writers
Posted on 09 Mar 2015
A Magnetic Resonance Spectroscopy (MRS) technique found multiple distinct premalignant changes in the biochemistry of breast tissue of women at high risk of breast cancer. The same changes were not recorded by conventional contrast-enhanced imaging 3-T Magnetic Resonance Imaging (MRI), and Ultrasound.

The discovery was made in a study carried out by a multidisciplinary team, including radiologists, radiographers, an MR physicist, and chemists. The study was published online in the March issue of the journal Radiology.

The study compared 14 women carrying BRCA2 gene mutations and nine women with BRCA1 mutations, with 10 healthy women that had no family history of breast cancer in a control group. All women underwent 2-D Localized Correlated Spectroscopy (L-COSY), and contrast enhanced 3-T MRI and ultrasound.

MRI or ultrasound scans did not show any abnormalities in the high-risk group, while L-COSY MRS found statistically significant biochemical changes in women with BRCA1 and BRCA2 gene mutations compared to controls.

Carolyn Mountford, MSc, D.Phil., from the University of Newcastle (Callaghan, Australia), said, “These changes appear to represent a series of early warning signs that may allow women to make informed decisions as to when and if they [should] have prophylactic mastectomy.”

Related Links:

University of Newcastle


Biopsy Software
Affirm® Contrast
Pocket Fetal Doppler
CONTEC10C/CL
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Ultrasound Needle Guidance System
SonoSite L25

Channels

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.